Results 331 to 340 of about 785,489 (353)

Predictive and prognostic value of genetic aberrations of EGFR-TKI treatment: a real-world analysis of <i>EGFR</i>-mutant non-small cell lung cancer. [PDF]

J Thorac Dis
Cheng Y, Liu Y, Lv X, Wang F, Wei M, Yin J, He C, Su S, Chen F, Wang L.   +9 more
europepmc   +1 more source

DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy

Jacqueline V. Aredo, Surbhi Singhal, Gerald J. Berry, Farshad Moradi, Heather A. Wakelee, Nathaniel J. Myall, Kavitha Ramchandran, Millie Das, Carlos J. Suarez, Joel W. Neal, Jonathan W. Riess   +10 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Nature Reviews Clinical Oncology, 2021
Alex Friedlaender, Vivek Subbiah, Alessandro Russo   +2 more
exaly   +2 more sources

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

New England Journal of Medicine, 2023
BACKGROUND Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
D. Planchard, P. Jänne, Ying Cheng, J. Yang, N. Yanagitani, Sang-we Kim, S. Sugawara, Yan Yu, Yun Fan, S. Geater, K. Laktionov, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, I. Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, Alex Todd, K. Kobayashi   +20 more
semanticscholar   +1 more source

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.

Current Topics in Medicinal Chemistry, 2020
The epidermal growth factor receptor (EGFR) belongs to ERBB family of tyrosine kinase receptor. EGFR signaling cascade is a key regulator in cell proliferation, differentiation, division, survival, and cancer development.
D. Sabbah, Rima Hajjo, K. Sweidan
semanticscholar   +1 more source

Overcoming therapy resistance in EGFR-mutant lung cancer

Nature Cancer, 2021
A. Passaro, P. Jänne, T. Mok, S. Peters
semanticscholar   +1 more source

EGFR activation limits the response of liver cancer to lenvatinib

Nature, 2021
Haojie Jin, Yaoping Shi, Yuanyuan Lv, S. Yuan, C. Ramirez, C. Lieftink, Liqin Wang, Siying Wang, Cun Wang, M. Dias, F. Jochems, Yuan Yang, A. Bosma, E. M. Hijmans, Marnix H. P. de Groot, S. Vegna, D. Cui, Yangyang Zhou, Jing Ling, Hui Wang, Yuchen Guo, Xing-ling Zheng, Nikita Isima, Haiqiu Wu, Chong Sun, R. Beijersbergen, L. Akkari, Weiping Zhou, B. Zhai, Wenxin Qin, R. Bernards   +30 more
semanticscholar   +1 more source

Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR–STAT3 signalling

Nature Cell Biology, 2021
Xinya Gao, Xin Xia, Fanying Li, Maolei Zhang, Huangkai Zhou, Xujia Wu, Jian Zhong, Zheng Zhao, Kun Zhao, Dawei Liu, Feizhe Xiao, Qiang Xu, Tao Jiang, Bo Li, Shi-Yuan Cheng, Nu Zhang   +15 more
semanticscholar   +1 more source

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly